Market Analysis

International Forum on Migraine

Theme : It's not just a Headache

Cenetri Publishing Group organizing the Migraine 2020 which is going to be held from March 09-10, 2020 in Lisbon, Portugal focusing on current and future advancements in Migraine. The theme of this year's meeting is "It's not just a Headache, which will provide an international platform for discussion and sharing of novel ideas for present and future expansions in treatment of Migraine.

The global migraine drugs market size is expected to be valued at USD 7.8 billion by 2025, as per a new report by Grand View Research, Inc., exhibiting an 18.0% CAGR during the forecast period. The market is largely driven by factors such as rise in disease prevalence, development of novel therapies, lifestyle changes, and hormonal medications. Migraine is a debilitating neurological disease characterized by recurrent attacks of severe throbbing head pain that can last for more than three days. Migraine pain may get worse on movement, preventing the patient from carrying out normal, day-to-day activities. In about one-third of attacks, both sides of the head, face, or neck are affected.

Over the past five years, the global migraine drugs market has been relatively stagnant, with the market mainly dominated by usage of generic triptans and other off-label drugs. Majority of the currently prescribed drugs for both acute and preventative treatment are associated with poor efficacy and an unfavorable side-effect profile. Launch of Amgen/ Novartis’ CGRP mAb Aimovig and Teva Pharma’s Ajovy is the first step toward revolutionizing the treatment paradigm of migraine prevention. For drug manufacturers likely to enter the market by 2019, such as Eli Lilly, Alder BioPharma, and Biohaven Pharma, pricing will be a key differentiating factor as all CGRP-based therapies have a similar efficacy and safety profile.

Report Scope

Attribute Details
Base year for estimation 2017
Forecast Period 2018 - 2025
Market Representation Revenue in USD Million & CAGR from 2017 to 2025
Country Scope U.S., U.K., Germany, Spain, Italy, France, Japan
Report coverage Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days) If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization